| pubmed-article:21257722 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21257722 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:21257722 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:21257722 | lifeskim:mentions | umls-concept:C0281466 | lld:lifeskim |
| pubmed-article:21257722 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:21257722 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:21257722 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:21257722 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:21257722 | pubmed:dateCreated | 2011-4-18 | lld:pubmed |
| pubmed-article:21257722 | pubmed:abstractText | Sphingosine 1-phosphate (S1P) is an important mediator of cancer cell growth and proliferation. Production of S1P is catalyzed by sphingosine kinase 1 (SphK). Safingol, (l-threo-dihydrosphingosine) is a putative inhibitor of SphK. We conducted a phase I trial of safingol (S) alone and in combination with cisplatin (C). | lld:pubmed |
| pubmed-article:21257722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21257722 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21257722 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21257722 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21257722 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:21257722 | pubmed:author | pubmed-author:GonenMithatM | lld:pubmed |
| pubmed-article:21257722 | pubmed:author | pubmed-author:SchwartzGary... | lld:pubmed |
| pubmed-article:21257722 | pubmed:author | pubmed-author:MerrillAlfred... | lld:pubmed |
| pubmed-article:21257722 | pubmed:author | pubmed-author:CarvajalRicha... | lld:pubmed |
| pubmed-article:21257722 | pubmed:author | pubmed-author:DicksonMark... | lld:pubmed |
| pubmed-article:21257722 | pubmed:author | pubmed-author:CaneLauren... | lld:pubmed |
| pubmed-article:21257722 | pubmed:copyrightInfo | ©2011 AACR. | lld:pubmed |
| pubmed-article:21257722 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21257722 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21257722 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:21257722 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21257722 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21257722 | pubmed:pagination | 2484-92 | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:meshHeading | pubmed-meshheading:21257722... | lld:pubmed |
| pubmed-article:21257722 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21257722 | pubmed:articleTitle | A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. | lld:pubmed |
| pubmed-article:21257722 | pubmed:affiliation | Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. | lld:pubmed |
| pubmed-article:21257722 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21257722 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| pubmed-article:21257722 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
